Literature DB >> 17568790

CDC25 phosphatases in cancer cells: key players? Good targets?

Rose Boutros1, Valérie Lobjois, Bernard Ducommun.   

Abstract

Cell division cycle 25 (CDC25) phosphatases regulate key transitions between cell cycle phases during normal cell division, and in the event of DNA damage they are key targets of the checkpoint machinery that ensures genetic stability. Taking only this into consideration, it is not surprising that CDC25 overexpression has been reported in a significant number of human cancers. However, in light of the significant body of evidence detailing the stringent complexity with which CDC25 activities are regulated, the significance of CDC25 overexpression in a subset of cancers and its association with poor prognosis are proving difficult to assess. We will focus on the roles of CDC25 phosphatases in both normal and abnormal cell proliferation, provide a critical assessment of the current data on CDC25 overexpression in cancer, and discuss both current and future therapeutic strategies for targeting CDC25 activity in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568790     DOI: 10.1038/nrc2169

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  256 in total

Review 1.  Role of Forkhead Box Class O proteins in cancer progression and metastasis.

Authors:  Chang Geun Kim; Hyemin Lee; Nehal Gupta; Sharavan Ramachandran; Itishree Kaushik; Sangeeta Srivastava; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2017-08-01       Impact factor: 15.707

2.  Multisite phosphoregulation of Cdc25 activity refines the mitotic entrance and exit switches.

Authors:  Lucy X Lu; Maria Rosa Domingo-Sananes; Malwina Huzarska; Bela Novak; Kathleen L Gould
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

3.  A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.

Authors:  Yongsheng Wu; Xiaoling Feng; Yucui Jin; Zhaojia Wu; William Hankey; Carolyn Paisie; Lei Li; Fengjuan Liu; Sanford H Barsky; Weiwei Zhang; Ramesh Ganju; Xianghong Zou
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-29

4.  The regulatory network of cell-cycle progression is fundamentally different in plants versus yeast or metazoans.

Authors:  Nico Dissmeyer; Annika K Weimer; Lieven De Veylder; Bela Novak; Arp Schnittger
Journal:  Plant Signal Behav       Date:  2010-12-01

5.  Computational modeling of the cell cycle.

Authors:  Eric A Sobie
Journal:  Sci Signal       Date:  2011-09-20       Impact factor: 8.192

6.  Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.

Authors:  Dewi Astuti; Mark R Morris; Wendy N Cooper; Raymond H J Staals; Naomi C Wake; Graham A Fews; Harmeet Gill; Dean Gentle; Salwati Shuib; Christopher J Ricketts; Trevor Cole; Anthonie J van Essen; Richard A van Lingen; Giovanni Neri; John M Opitz; Patrick Rump; Irene Stolte-Dijkstra; Ferenc Müller; Ger J M Pruijn; Farida Latif; Eamonn R Maher
Journal:  Nat Genet       Date:  2012-02-05       Impact factor: 38.330

Review 7.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

Review 8.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

Review 9.  In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Authors:  Hiroaki Kiyokawa; Dipankar Ray
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

10.  SIRT6 inhibits colorectal cancer stem cell proliferation by targeting CDC25A.

Authors:  Wenguang Liu; Manwu Wu; Hechun Du; Xiaoliang Shi; Tao Zhang; Jie Li
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.